iBio reports Q2 FY2026 operating loss; secures $26M PIPE financing led by Frazier Life Sciences

iBio, Inc.

2026-Q2 EPS reported -$0.19 revenue$100,000

No revenue for Q2 ended Dec 31, 2025, vs $0.2M a year ago; R&D expense $4.3M, G&A $5.2M (includes impairment of IBIO-101 intangible).
Cash and investments of $52.7M at Dec 31, 2025; net proceeds of ~$24.4M from January PIPE extend runway into Q3 FY2028.
IBIO-600 (myostatin antibody) on track for Phase 1a clinical trial in H1 2026; IBIO-610 (activin E) aims for first human trials early 2027.
NHP data for IBIO-610 shows predicted human half-life up to 100 days, supporting twice-yearly dosing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.